A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Fioravanti, Mario ^a   Nakashima, Taku ^b   Xu, Jun ^c   Garg, Amit ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c Jiangsu Province Geriatric Hospital   (China)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERGOTAMINE; ERGOTOXINE; NICERGOLINE; PLACEBO; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ADVERSE DRUG REACTION; AGITATION; ALZHEIMER DISEASE; ANXIETY; CEREBROVASCULAR DISEASE; COCHRANE LIBRARY; DEMENTIA; DIARRHEA; DIZZINESS; DROWSINESS; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ERGOTISM; EUROPEAN MEDICINES AGENCY; FATIGUE; FIBROSIS; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INSOMNIA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; BRAIN DISEASES; PERIPHERAL VASCULAR DISEASES;

ADRENERGIC ALPHA-ANTAGONISTS; BRAIN DISEASES; HUMANS; NEUROPROTECTIVE AGENTS; NICERGOLINE; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904975174     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005090     Document Type: Review

References (44)

1. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001;(4):CD003159.
2. Carfagna N, Di Clemente A, Cavanus S, et al. Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Neurosci Lett 1995;197:195-8.
3. Carfagna N, Rossi A. Nicergoline: biochemical studies on neuronal metabolism. Funct Neurol 1989;4:177-85.
4. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig 2008;28:533-52.
5. New restrictions on use of medicines containing ergot derivatives. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/06/ WC500144861.pdf
6. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
7. Arrigo A, Moglia A, Borsotti L. A double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia. Int J Clin Pharmacol Res 1982;2:33-41. (Pubitemid 13103400)
8. Battaglia A, Bruni G, Ardia A, et al. Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J Am Geriatr Soc 1989;37:295-302. (Pubitemid 19084795)
9. Battalgia A, Bruni G, Sacchetti G, et al. A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr Therap Res 1990;48:597-612. (Pubitemid 20381571)
10. Battaglia A, Annoni K, Pamparana F, et al. Nicergoline in the Long Term Treatment of Mild or Moderate Senile Dementia. A Multicenter Double-blind, Randomized, Placebo-controlled Trial. In 8th European College of Neuropsychopharmacology Congress: 30th September - 4th October 1995; Venice.
11. Bes A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313-22. (Pubitemid 29250991)
12. Bossi L. Buflomedil and nicergolin in the treatment of acute cerebral ischaemia. A double-blind, randomized comparative study. Minerva Med 1985;76:1005-18. (Pubitemid 15073319)
13. Brola W. Evaluation of treatment outcome after nicergoline and pentoxifylline in patients with ischemic stroke. Przegl Lek 1997;54:79-82.
14. Cascone A, Liverta C, Pollini C. A double-blind trial of nicergolin and placebo in cerebral and peripheral cerebrovascular disturbance in the aged. Minerva Cardioangiol 1978;26:95-100. (Pubitemid 8306760)
15. Colombeau P, Ballanger P. Results of the double-blind use of an alpha blockader, nicergoline, in cervico-prostatic dysfunctions. J Urol 1987;93:533-5.
16. Crook TH. Nicergoline in the treatment of probable Alzheimer's disease preliminary results of a double-blind, randomized, placebo-controlled study. J Neurol Sci 1997;150:S18.
17. Dubreuil C. Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline. Presse Med 1986;15:1559-61. (Pubitemid 16018126)
18. Felisati G, Battaglia A, Papini MG, et al. Nicergoline in balance alterations in adult and elderly patients: a double-blind, placebo-controlled study. Clin Drug Investig 2002;22:731-40. (Pubitemid 35388183)
19. Forette F, Varin D, Henry JF, et al. Treatment of arterial hypertension in the elderly with an alpha-blocker: nicergoline (author's transl). La Nouvelle Presse Méd 1980;9:3685-8. (Pubitemid 11194509)
20. Gessner B, Voelp A, Klasser M. Study of the long-term action of a Gingkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. Arzneimittelforschung 1985;35:1459-65. (Pubitemid 15230661)
21. Herrmann WM. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997;8:9-17. (Pubitemid 27173512)
22. Kugler JE, Meurer-Krull BC. Electroencephalography and psychometric measurements during the treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesylate. Arzneimittelforschung 1985;35:1865-70. (Pubitemid 16212404)
23. Lu JH. Nicergoline in treatment of vascular dementia: a consecutive, multicenter, double-blind clinical trial. Chin J Neurol 2001:88-91.
24. Marolda M, Fragassi N, Buscaino GA. Clinical evaluation of (-) eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia. Eur Neurol 1978;17:159-66. (Pubitemid 10229801)
25. Materna F. Leading symptom vertigo: comparative study with flunarizine and nicergoline. Med Klin 1985;80:292-5. (Pubitemid 15074455)
26. Nakashima T, Hattori N, Okimoto M, et al. Nicergoline improves dysphagia by upregulating substance p in the elderly. Medicine 2011;90:279-83.
27. Nappi G, Bono G, Merlo P, et al. Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Investig 1997;13:308-16. (Pubitemid 27279632)
28. Nishiyama Y, Abe A, Ueda M, et al. Nicergoline increases serum substance P levels in patients with an ischaemic stroke. Cerebrovasc Dis 2010;29:194-8.
29. Pilkowska E, Jakubowska T, Witkowska K, et al. Nicergoline in the treatment of patients after a mild ischemic stroke. Neurol Neurochir Pol 2002;36:1075-85.
30. Pogliani E, Della Volpe A, Ferrari R. Inhibition of human platelet aggregation by oral administration of nicergoline. A double blind study. Farmaco Prat 1975;30:630-40.
31. Ronchi F, Margonato A, Ceccardi R. Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation. Urol Res 1982;10:131-4. (Pubitemid 12046995)
32. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double blind, placebo controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-95.
33. Setyopranoto ISP. Role of nicergoline 60 miligram per oral for improvement of the patients with acute ischemic stroke. J Neurol Sci 2009;285:S221-2.
34. Winblad B, Bonura ML, Rossini BM, et al. Nicergoline in the treatment of mild-to-moderate Alzheimer's disease: a European multicentre trial. Clin Drug Investig 2001;21:621-32. (Pubitemid 32937981)
35. Zucconi V, Terzi Bolaffio M. Results with nicergolin and dihydroergotoxine in 30 hemiplegics in the postacute phase. Minerva Med 1974;65:936-45.
36. Alvarez-Guerra M, Bertholom N, Garay RP. Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat. Fundam Clin Pharmacol 1999;13:50-8.
37. Shintomi K, Yoshimoto K, Ogawa Y, et al. Effects of nicergoline on cerebral energy metabolism in normal mice. Yakugaku Zasshi 1986;106:90-4. (Pubitemid 16132552)
38. Sortino MA, Battaglia A, Pamparana F, et al. Neuroprotective effects of nicergoline in immortalized neurons. Eur J Pharmacol 1999;368:285-90. (Pubitemid 29117151)
39. Bousquet J, Rivory JP, Maheut M, et al. Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol 1989;83:825-8. (Pubitemid 19127951)
40. Akisada T, Orita Y, Sato Y, et al. Effect of nicergoline on vertigo and tinnitus. Pract Otol 1994;87:845-55. (Pubitemid 24201403)
41. Boismare F, Lefrancois J. Haemodynamic effects of nicergoline in man at rest and during exercise. Clin Exp Pharmacol Physiol 1980;7:105-12. (Pubitemid 10128775)
42. Gallego J, Forner V, Jimenez F, et al. Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report. Paraplegia 1984;22:216-24.
43. Kim MJ, Chang JH, Lee SK, et al. Acute interstitial nephritis due to nicergoline (Sermion). Nephron 2002;92:676-9.
44. Ergot-derived dopamine agonists: risk of fibrotic reactions in chronic endocrine uses. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON087807